US 11806398
Citrate buffered VEGF antagonist formulations
granted A61KA61K31/4172A61K31/7012
Quick answer
US patent 11806398 (Citrate buffered VEGF antagonist formulations) held by REGENERON PHARMACEUTICALS, INC. expires Mon Nov 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Nov 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 28
- CPC classes
- A61K, A61K31/4172, A61K31/7012, A61K38/16, A61K38/179